Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03224546 · ClinicalTrials.gov registry record · NA

Cocaine Use Reduction and Health

A NA study, sponsored by William Stoops.

Completed
Registry status
NA
Development phase
127
Enrollment target

NCT03224546: Completed NA study, sponsored by William Stoops.

NCT03224546 is a NA study that has completed, run by William Stoops. The registered enrollment target is 127 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03224546, a NA study, has completed, sponsored by William Stoops.

COMPLETED
Registry status
NA
Development phase
127 participants
Enrollment target

Study Summary

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced cocaine use. These data will be used to change current accepted cocaine treatment endpoints and accelerate identification of therapies for cocaine use disorder.

Primary Outcome

Endothelin-1 levels will be measured. They will be recorded in pg/ml.

Interventions

  • BEHAVIORAL Contingency Management

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2017-09-15
Est. Completion 2024-01-15
Phase NA
William Stoops

13 total trials

What the finished NCT03224546 record still lists

NCT03224546 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Contingency Management is the first listed.

NCT03224546 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03224546 about?

NCT03224546 is a clinical study titled "Cocaine Use Reduction and Health". Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating ...

What is the current status of trial NCT03224546?

This trial is currently completed. It is a NA study. The enrollment target is 127 participants. The study started on 2017-09-15. Estimated completion is 2024-01-15.

What interventions are being tested in trial NCT03224546?

The interventions under investigation include: Contingency Management (BEHAVIORAL).

Who is sponsoring clinical trial NCT03224546?

This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03224546's enrollment target sits among peer trials

127 749th of 2000 higher than 1,252 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03017820 · 127 participants · Phase 1

    A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

  • NCT03609580 · 127 participants · Phase 1

    Post-operative Urinary Retention (POUR) Following Thoracic Surgery

  • NCT06285643 · 127 participants · Phase 2

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  • NCT06809400 · 127 participants · Phase 1

    A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03224546, the US trial registry maintained by the National Library of Medicine. NCT03224546 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.